TAYLOR, Catherine, A.,KIU, Zhongda,TANG, Terence,DONDERO, Richard, S.,THOMPSON, John, E.
申请号：
USUS2013/038803
公开号：
WO2013/165973A1
申请日:
2013.04.30
申请国别(地区):
WO
年份:
2013
代理人:
摘要：
The present invention relates to the treatment of multiple myeloma in a human subject comprising administering lenadlidomide in combination with a vector which expresses a human elF-SAI which is unable to be hypusinated and an siRNA which targets elF-SAI. In some embodiments, the lenalidomide is administered simultaneously with the vector and the siRNA while in some embodiments the lenalidomide is administered at a time that is different from when the vector and the siRNA are administered. In some embodiments, the lenalidomide is administered orally and the vector and the siRNA are administered intraveneously.La présente invention concerne le traitement dun myélome multiple chez un sujet humain comprenant ladministration de lénalidomide en combinaison avec un vecteur qui exprime un elF-5A1 humain qui ne peut pas être hypusiné, et un ARNsi qui cible lelF-5A1.
